How to Buy Gilead Sciences Stock
Gilead Sciences Inc
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets.
Gilead Sciences stock last closed at $167.95, up 0.08% from the previous day, and has increased 34.25% in one year. It has overperformed other stocks in the Drug Manufacturers - General industry by 0.06 percentage points. Gilead Sciences stock is currently +43.69% from its 52-week low of $116.88, and -4.89% from its 52-week high of $176.58.
There are currently 1.24B GILD shares outstanding. The market value of GILD is $208.31B. In the last 24 hours, 4.23M GILD shares were traded.
How to Buy Gilead Sciences Stock
Not sure how to invest in Gilead Sciences stock? Here's how.
- Decide where to buy Gilead Sciences stock: You need to pick an online brokerage, but don't worry - we've researched dozens of online brokerages and apps to help you decide where to buy Gilead Sciences stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Deposit funds into your brokerage account: Choose your method of payment and add your details.
- Analyze Gilead Sciences stock: The Gilead Sciences ticker symbol is GILD. Is Gilead Sciences stock a good investment? Should you buy shares of GILD? How do GILD's underlying business fundamentals look? Do top analysts think Gilead Sciences is a good buy? Why has GILD's stock price moved recently? (Hint: Our stock analysis website can help you figure out if GILD is a good stock to buy).
- Execute your GILD purchase: Decide if you will purchase GILD shares at the current market price or use a limit order to buy GILD shares at a specific price.
- Keep tabs on your investment in GILD: Create a watchlist to track your position in Gilead Sciences shares.
Step 1: Decide where to buy Gilead Sciences stock
You will need an online brokerage account to access the NASDAQ market and buy GILD stock.
Our favorite brokerage: eToro
Based on our research, eToro is the best brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to world markets: From Technology to Real Estate, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've picked the right brokerage, you need to fill out some personal details so you can invest in GILD today.
How to Set Up a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal details to open a new brokerage account.
- Submit your details by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you've filled out your info on one of the most highly reviewed stock market apps, you can securely and quickly fund your account:
Watch the tutorial below to see the process of transferring funds into your new investment account.
Step 4: Analyze Gilead Sciences stock
After you have decided on the best place to buy Gilead Sciences stock, it's crucial to research their stock prior to buying, so you truly wrap your head around the risk and opportunity.
Gilead Sciences stock data
Gilead Sciences Overview
WallStreetZen was designed to help everyday investors do more accurate fundamental analysis in less time.
You can see all of the due diligence checks on GILD's stock page.
Is GILD stock undervalued?
You can use many financial metrics, analyses, models, and charts to gauge GILD's intrinsic value.
Using relative valuations measures:
- GILD may be overvalued based on its P/B ratio of 15.98x, relative to Drug Manufacturers - General industry P/B ratio of 8.66x
You can do additional valuation analysis on GILD's stock here.
GILD Financial Health Summary
Positive Health Checks:
- GILD's operating cash flow of $14.48B allows it to safely service it's debt of $26.23B.
- There are more short-term assets than short-term liabilities on the GILD balance sheet.
Negative Health Checks:
- GILD has a relatively high debt to equity ratio of 2.95.
- GILD profit margin has gone down from 27.9% to -12.5% in the past year.
- There are more long-term liabilities than short-term assets on the GILD balance sheet.
- GILD earnings of -$1.52B is not enough to cover its interest payments.
- Total GILD debt is higher than 5 years ago, relative to shareholder equity.
Is it a good time to buy Gilead Sciences stock, according to Wall Street analysts?
Out of 16 Wall Street analysts who monitor GILD, the consensus analyst rating on GILD is a Strong Buy
Please keep in mind that analyst ratings are not recommendations, nor are they financial advice.
Most Recent GILD Analyst Ratings
Matthew Harrison, a top 19% analyst from Morgan Stanley maintains GILD with a strong buy rating and raises their GILD price target from $163.00 to $183.00, on Oct 30, 2026.
Mohit Bansal, a top 10% analyst from Wells Fargo maintains GILD with a strong buy rating and raises their GILD price target from $165.00 to $190.00, on Oct 30, 2026.
Gregory Renza, a top 2% analyst from Truist Securities maintains GILD with a strong buy rating and raises their GILD price target from $158.00 to $181.00, on Oct 30, 2026.
Brian Abrahams, a top 15% analyst from RBC Capital maintains GILD with a hold rating and raises their GILD price target from $126.00 to $131.00, on Oct 30, 2026.
Carter Gould, a top 8% analyst from Cantor Fitzgerald maintains GILD with a strong buy rating and raises their GILD price target from $155.00 to $175.00, on Oct 30, 2026.
Cantor Fitzgerald's Carter Gould raised their price target on Gilead Sciences (NASDAQ: GILD) by 12.9% from $155 to $175 on 2026/10/30. The analyst maintained their Strong Buy rating on the stock.
Gilead Sciences reported its Q3 2026 earnings.
Based on robust demand for HIV treatment and PrEP, the quarter beat the revenue consensus by $518M, Gould told readers.
As a result, the analyst predicted that FY 2026 (ex-Veklury) and HIV growth would be 10% to11% and 12%, respectively, higher than pre-print forecasts.
Earnings Report
For Q3 2026, Gilead Sciences reported:
- EPS of $2.55, which beat the Zacks Consensus Estimate of $2.17 and, by 3.2%, Q3 2025 $2.47.
- Revenue of $8.3B, which beat the Zacks Consensus Estimate by 6.21% and, by 13%, Q3 2025’s $7.77B.
For FY 2026, management guided:
- Loss per share of $1.20 to $0.85.
- Revenue of $31B to $31.3B.
Chairman & CEO Daniel O’Day commented: “Gilead delivered an exceptional Q3, with our strongest Y/Y base business growth in more than a decade, reflecting the strength, breadth and durability of our business.
“Our performance enabled us to raise our FY base business revenue guidance again this quarter, bringing the total increase to $1.6B since the start of 2026.
“Our HIV business grew 18%, and HIV prevention sales nearly doubled Y/Y.
“With multiple ongoing and potential launches across HIV and Oncology, important progress in Inflammation and a disciplined operating model, Gilead is well positioned for business growth and impact for patients.”
You can dig deeper into what analysts are projecting on the Gilead Sciences stock forecast page.
GILD Trading Indicators
GILD Performance Numbers
Last year, GILD revenue was $30.99B. During the last 5 year, GILD's revenue has grown by 2.43% per year. This was slower than the Drug Manufacturers - General industry average of 10.85%.
Dig into GILD's earnings and revenue performance here.
What are GILD insiders up to?
In the past 12 months, insiders at GILD have sold more shares than they have bought.
Wettan Keeley M. Cain, EVP of GILD, was the latest GILD insider to sell. They sold $557,809.89 worth of GILD stock on Nov 6, 2026.
Learn more about who owns GILD shares here.
Does GILD stock generate passive income?
Gilead Sciences pays a dividend of 1.94%, compared to the Drug Manufacturers - General industry's average dividend yield of 2.48%. If you owned $1,000 worth of GILD stock, you would have received $19.35 last year.
Gilead Sciences dividend payments have consistently grown over the past decade and have remained stable.
Get more data about Gilead Sciences dividend yield and history here.
What others are saying about GILD
One of the biggest reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Execute your GILD purchase
You have two primary order types:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are mostly fine for most investors. - Limit order: A limit order enables you to buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at a particular price, use a limit order.
Hit the Open Trade button and your broker will place your order.
If you want additional help buying stocks on eToro, click the how to video below:
Step 6: Keep tabs on your investment in GILD
Now that you own some GILD stock, you'll want to keep up with your new stock purchase.
Create a watchlist to get notified of the latest news about your GILD stock.
GILD Feed
How to Buy Stock in Gilead Sciences
To summarize, here are the 6 steps for buying Gilead Sciences stock:
- Decide where to buy Gilead Sciences stock
- Sign up for your brokerage account
- Deposit funds into your brokerage account
- Analyze Gilead Sciences stock
- Execute your GILD purchase
- Keep tabs on your investment in GILD
If you are looking for a brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you want to get the latest news on your investment in Gilead Sciences, click the button below.
Related "How To" Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.